@article{discovery10064636, month = {July}, pages = {799--812}, journal = {Biomarkers in Medicine}, note = {This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.}, publisher = {FUTURE MEDICINE LTD}, year = {2018}, volume = {12}, number = {7}, title = {Update on biomarkers for amyloid pathology in Alzheimer's disease}, keywords = {A{\ensuremath{\beta}}, Alzheimer's disease, amyloid-{\ensuremath{\beta}}, biomarkers, blood-based biomarkers, cerebrospinal fluid, dementia, positron emission tomography}, issn = {1752-0371}, abstract = {At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-{\ensuremath{\beta}} (A{\ensuremath{\beta}}) into oligomers, fibrils and plaques. Effective monitoring of A{\ensuremath{\beta}} deposition directly in patients is essential to assist anti-A{\ensuremath{\beta}} therapeutics in target engagement and participant selection. In the advent of approved anti-A{\ensuremath{\beta}} therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established A{\ensuremath{\beta}} biomarkers are widely utilized: A{\ensuremath{\beta}}-binding ligands for positron emission tomography and immunoassays to measure A{\ensuremath{\beta}}42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for A{\ensuremath{\beta}} pathology. Furthermore, we will explore the current application of blood-based markers to assess A{\ensuremath{\beta}} pathology.}, url = {http://doi.org/10.2217/bmm-2017-0433}, author = {Ashton, NJ and Schoell, M and Heurling, K and Gkanatsiou, E and Portelius, E and Hoeglund, K and Brinkmalm, G and Hye, A and Blennow, K and Zetterberg, H} }